CDK/HDAC-IN-2

• Description :

  CDK/HDAC-IN-2 is a potent HDAC/CDK dual inhibitor with IC50 of 6.4, 0.25, 45, >1000, 8.63, 0.30, >1000 nM for HDAC1, HDAC2, HDAC3, HDAC6,8, CDK1, CDK2, CDK4,6,7, respectively. CDK/HDAC-IN-2 shows excellent antiproliferative activities. CDK/HDAC-IN-2 induces apoptosis and cell cycle arrest at G2/M phase. CDK/HDAC-IN-2 shows potent antitumor efficacy[1].

• UNSPSC :

  12352005

• Target :

  Apoptosis; CDK; HDAC

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage; Epigenetics

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/cdk-hdac-in-2.html

• Solubility :

  10 mM in DMSO

• Smiles :

  NC1=CC=CC=C1NC(C2=CC=C(C=C2)CNC(C3=NNC=C3NC(C4=C(C=CC=C4Cl)Cl)=O)=O)=O

• Molecular Formula :

  C25H20Cl2N6O3

• Molecular Weight :

  523.37

• References & Citations :

  [1]Cheng C, et al. Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity. Eur J Med Chem. 2020 Mar 1;189:112073.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CDK1; CDK2; CDK4; CDK6; CDK7; HDAC1; HDAC2; HDAC3; HDAC6; HDAC8

• CAS Number :

  [2580938-58-3]